Conformationally sampled pharmacophore for peptidic δ opioid ligands

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7773-7780

  Bernard, Denzil ^a   Coop, Andrew ^a   MacKerell Jr , Alexander D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; DELTORPHIN I; DELTORPHIN II; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; LEUCINE ENKEPHALIN; METENKEPHALIN; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONALLY SAMPLED PHARMACOPHORE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; LIGAND BINDING; METHODOLOGY; MOLECULAR DYNAMICS; PHARMACOPHORE; PROTEIN STRUCTURE; SIMULATION;

ANALGESICS, OPIOID; HYDROPHOBICITY; LIGANDS; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, OPIOID, DELTA;

EID: 28144465246     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050785p     Document Type: Article

References (55)

1. Coop, A.; Rice, K. C. Role of δ-Opioid Receptors in Biological Processes. Drug News Perspect. 2000, 13, 481-487.
2. Wells, J. L.; Bartlett, J. L.; Ananthan, S.; Bilsky, E. J. In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid μ-Agonist/δ-Antagonist That Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence. J. Pharmacol. Exp. Ther. 2001, 297, 597-605.
3. Joseph-McCarthy, D. Computational Approaches to Structure-Based Ligand Design. Pharmacol. Ther. 1999, 84, 179-191.
4. Klebe, G. Recent Developments in Structure-Based Drug Design. J. Mol. Med. 2000, 78, 269-281.
5. Loew, G. H.; Villar, H. O.; Alkorta, I. Strategies for Indirect Computer-Aided Drug Design. Pharm. Res. 1993, 10, 475-486.
6. Satoh, M.; Minami, M. Molecular Pharmacology of the Opioid Receptors. Pharmacol. Ther. 1995, 68, 343-364.
7. Knapp, R. J.; Malatynska, E.; Collins, N.; Fang, L.; Wang, J. Y.; et al. Molecular Biology and Pharmacology of Cloned Opioid Receptors. FASEB J. 1995, 9, 516-525.
8. Metzger, T. G.; Ferguson, D. M. On the Role of Extracellular Loops of Opioid Receptors in Conferring Ligand Selectivity. FEBS Lett. 1995, 375, 1-4.
9. Metzger, T. G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. Application of the Message-Address Concept to the Docking of Naltrexone and Selective Naltrexone-Derived Opioid Antagonists into Opioid Receptor Models. Neurochem. Res. 1996, 21, 1287-1294.
10. Alkorta, I.; Loew, G. H. A 3D Model of the Delta Opioid Receptor and Ligand-Receptor Complexes. Protein Eng. 1996, 9, 573-583.
11. Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid Receptor Three-Dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints. Biophys. J. 1998, 75, 612-634.
12. Filizola, M.; Carteni-Farina, M.; Perez, J. J. Molecular Modeling Study of the Differential Ligand-Receptor Interaction at the Mu, Delta and Kappa Opioid Receptors. J. Comput.-Aided Mol. Des. 1999, 13, 397-407.
13. Filizola, M.; Laakkonen, L.; Loew, G. H. 3D Modeling, Ligand Binding and Activation Studies of the Cloned Mouse Delta, Mu, and Kappa Opioid Receptors. Protein Eng. 1999, 12, 927-942.
14. Mosberg, H. I. Complementarity of Delta Opioid Ligand Pharmacophore and Receptor Models. Biopolymers 1999, 51, 426-439.
15. Huang, P.; Kim, S.; Loew, G. Development of a Common 3D Pharmacophore for Delta-Opioid Recognition from Peptides and Non-Peptides Using a Novel Computer Program. J. Comput.-Aided Mol. Des. 1997, 11, 21-28.
16. Coop, A.; Jacobson, A. E. The LMC Opioid Reconition Pharmacophore: Comparison of SNC80 and Oxymorphindole. Bioorg. Med. Chem. Lett. 1999, 9, 357-362.
17. Bernard, D.; Coop, A.; MacKerell, A. D., Jr. 2D Conformationally Sampled Pharmacophore: A Ligand-based Pharmacophore To Differentiate δ Opioid Agonists from Antagonists. J. Am. Chem. Soc. 2003, 125, 3101-3107.
18. Schullery, S. E.; Mohammedshah, T.; Makhlouf, H.; Marks, E. L.; Wilenkin, B. S.; et al. Binding to Delta and Mu Opioid Receptors by Deltorphin I/II Analogues Modified at the Phe(3) and Asp(4)/Glu(4) Side Chains: A Report of 32 New Analogues and a QSAR Study. Bioorg. Med. Chem. 1997, 5, 2221-2234.
19. Schullery, S. E.; Rodgers, D. W.; Tripathy, S.; Jayamaha, D. E.; Sanvordekar, M. D.; et al. The Role of Backbone Conformation in Deltorphin II Binding: A QSAR Study of New Analogues Modified in the 5-, 6-Positions of the Address Domain. Bioorg. Med. Chem. 2001, 9, 2633-2642.
20. Heyl, D. L.; Schullery, S. E.; Renganathan, K.; Jayamaha, M. N.; Rodgers, D. W.; et al. pK(a) and Volume of Residue One Influence Delta/Mu Opioid Binding: QSAR Analysis of Tyrosine Replacement in a Nonselective Deltorphin Analogue. Bioorg. Med. Chem. 2003, 11, 3761-3768.
21. Rodgers, D. W.; Renganathan, K.; Jayamaha, M. N.; Schullery, S. E.; Heyl, D. L. QSAR Analysis of Ring-Substituted Tyrosine Replacements at the N-Terminus of a Nonselective Deltorphin Analog. Biopolymers 2003, 71, 372-372.
22. Peng, Y.; Keenan, S. M.; Zhang, Q.; Kholodovych, V.; Welsh, W. J. 3D-QSAR Comparative Molecular Field Analysis on Opioid Receptor Antagonists: Pooling Data from Different Studies. J. Med. Chem. 2005, 48, 1620-1629.
23. Wilkes, B. C.; Schiller, P. W. Theoretical Conformational-Analysis of the Opioid Delta-Antagonist H-Tyr-Tic-Phe-Oh and the Mu-Agonist H-Tyr-D-Tic-Phe-NH2. Biopolymers 1994, 34, 1213-1219.
24. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; et al. Selective Opioid Dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
25. Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. Development of a Model for the Delta-Opioid Receptor Pharmacophore. 3. Comparison of the Cyclic Tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]-OH with Other Conformationally Constrained Delta-Receptor Selective Ligands. Biopolymers 1996, 38, 221-234.
26. Mosberg, H. I.; Dua, R. K.; Pogozheva, I. D.; Lomize, A. L. Development of a Model for the Delta-Opioid Receptor Pharmacophore. 4. Residue 3 Dehydrophenylalanine Analogues of Tyr-c[D-Cys-Phe-D-Pen]OH(JOM-13) Confirm Required Gauche Orientation of Aromatic Side Chain. Biopolymers 1996, 39, 287-296.
27. Brandt, W. A Uniform Molecular Model of Delta Opioid Agonist and Antagonist Pharmacophore Conformations. J. Comput.-Aided Mol. Des. 1998, 12, 615-621.
28. Bernard, D.; Coop, A.; MacKerell, A. D., Jr. Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands. Drug Des. Rev.-Online 2005, 2, 277-291.
29. McQuarrie, D. A. Statistical Mechanics; Harper Collinns Publishers: New York, 1976; pp 452-466.
30. MacKerell, A. D., Jr. Empirical Force Fields for Biological Macromolecules: Overview and Issues. J. Comput. Chem. 2004, 25, 1584-1604.
31. Nicklaus, M. C.; Wang, S.; Driscoll, J. S.; Milne, G. W. A. Conformational Changes of Small Molecules Binding to Proteins. Bioorg. Med. Chem. 1995, 3, 411-428.
32. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258, 577-580.
33. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous Opioid Peptides: Multiple Agonists and Receptors. Nature 1977, 267, 495-499.
34. Feig, M.; Karanicolas, J.; Brooks, C. L., III. MMTSB Tool Set: Enhanced Sampling and Multiscale Modeling Methods for Applications in Structural Biology. J. Mol. Graphics Modell. 2004, 22, 377-395.
35. Okura, T.; Varga, E. V.; Hosohata, Y.; Navratilova, E.; Cowell, S. M.; et al. Agonist-Specific Down-Regulation of the Human δ-Opioid Receptor. Eur. J. Pharmacol. 2003, 459, 9-16.
36. Lecoq, I.; Marie, N.; Jauzac, P.; Allouche, S. Different Regulation of Human δ-Opioid Receptors by SNC-80 [(+)-4-[(αR)-α-((2S,5R)-4- Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Endogenous Enkephalins. J. Pharmacol. Exp. Ther. 2004, 310, 666-677.
37. Varga, E. V.; Navratilova, E.; Stropova, D.; Jambrosic, J.; Roeske, W. R.; et al. Agonist-Specific Regulation of the δ-opioid Receptor. Life Sci. 2004, 76, 599-612.
38. SYBYL, version 6.2; Tripos Associates: St. Louis, MO, 2002.
39. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; et al. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
40. MacKerell, A. D., Jr.; Brooks, B.; Brooks, C. L.; Nilsson, L.; Roux, B.; et al. CHARMM: The Energy Function and Its Parameterization with an Overview of the Program. In Encyclopedia of Computational Chemistry; Schleyer, P. v. R., Allinger, N. L., Clark, T., Gasteiger, J., Kollman, P. A., et al., Eds.; John Wiley & Sons: Chichester, U.K., 1998; pp 271-277.
41. Halgren, T. A. The Merck Molecular Force Field: I. Basis, Form, Scope, Parameterization and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
42. Halgren, T. A. Merck Molecular Force Field: II. MMFF94 van der Waals and Electrostatic Parameters for Intermolecuolar Interactions. J. Comput. Chem. 1996, 17, 520-552.
43. Allen, M. P.; Tildesley, D. J. Computer Simulation of Liquids: Oxford University Press: New York, 1989.
44. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. J. Comput. Phys. 1977, 23, 327-341.
45. Im, W.; Lee, M. S.; Brooks, C. L., III. Generalized Born Model with a Simple Smoothing Function. J. Comput. Chem. 2003, 24, 1691-1702.
46. Im, W.; Feig, M.; Brooks, C. L., III. An Implicit Membrane Generalized Born Theory for the Study of Structure, Stability, and Interactions of Membrane Proteins. Biophys. J. 2003, 85, 2900-2918.
47. Lee, M. S.; Salsbury, F. R., Jr.; Brooks, C. L., III. Novel Generalized Born Methods. J. Chem. Phys. 2002, 116, 10606-10614.
48. Lee, M. S.; Feig, M.; Salsbury, F. R., Jr.; Brooks, C. L., III. New Analytical Approximation to the Standard Molecular Volume Definition and Its Application to Generalized Born Calculations. J. Comput. Chem. 2003, 24, 1348-1356.
49. Mallik, B.; Morikis, D. Development of a Quasi-Dynamic Pharmacophore Model for Anti-Complement Peptide Analogues. J. Am. Chem. Soc. 2005, 127, 10967-10976.
50. Metropolis, N.; Rosembluth, A.; Rosembluth, M.; Teller, A. Equation of State Calculations by Fast Computing Machines. J. Chem. Phys. 1953, 21, 1087-1092.
51. Sanbonmatsu, K. Y.; Garcia, A. E. Structure of Met-enkephalin in Explicit Aqueous Solution Using Replica Exchange Molecular Dynamics. Proteins 2002, 46, 225-234.
52. Wilkes, B. C.; Schiller, P. W. Comparative-Analysis of Various Proposed Models of the Receptor-Bound Conformation of H-Tyr-Tic-Phe-OH Related Delta-Opioid Antagonists. Biopolymers 1995, 37, 391-400.
53. Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M. D.; Wilkes, B. C.; et al. The TIPP Opioid Peptide Family: Development of Delta Antagonists, Delta Agonists, and Mixed Mu Agonist/Delta Antagonists. Biopolymers 1999, 51, 411-425.
54. Morley, J. S. Structure-Activity Relationships of Enkephalin-like Peptides. Annu. Rev. Pharmacol. Toxicol. 1980, 20, 81-110.
55. Portoghese, P. S.; Sultana, M.; Moe, S. T.; Takemori, A. E. Synthesis of Naltrexone-Derived δ-Opiod Antagonists. Role of the àAddress Moiety. J. Med. Chem. 1994, 37, 579-585.